Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLASSIA and Institution standard of care · 1 trial · 1 indication
Incidence of subjects experiencing causally related AEs and/or SAEs
| Arm | Type | Description |
|---|---|---|
| GLASSIA® | EXPERIMENTAL | Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion. |
| Institution standard of care (SOC) | NO_INTERVENTION | Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion. |
| Name | Type | Description |
|---|---|---|
| GLASSIA® and Institution standard of care (SOC) | DRUG | Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC) |
Inclusion Criteria: 1. Signed and dated informed consent. 2. Age ≥18 years. 3. Subject is planned to undergo first single or double lung transplant (including heart-lung transplant) as per standard implantation procedure. Exclusion Criteria: 1. Subject has immunoglobulin A (IgA) deficiency and kn...
GLASSIA is being studied for use in lung transplantation to address lung rejection. A Phase 2 clinical trial evaluated the safety and efficacy of intravenous GLASSIA treatment in lung transplant patients. The study enrolled 30 participants in Israel and has been completed.
GLASSIA is developed by Kamada Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KMDA. The company conducted a Phase 2 clinical trial of GLASSIA for lung transplantation and lung rejection.
GLASSIA is in Phase 2 clinical development for lung rejection in the context of lung transplantation. A single Phase 2 trial, NCT02614872, has been completed. The drug remains investigational and is not approved for this indication.
GLASSIA has one completed clinical trial, NCT02614872, titled 'Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation.' This Phase 2 study enrolled 30 participants aged 18 years and older in Israel and was not double-blinded.
Yes, GLASSIA and Glassia refer to the same drug product. The clinical trial NCT02614872 uses the name 'Glassia®' in its title, while the drug is commonly referred to as GLASSIA. Both names denote the same investigational treatment for lung rejection.